Ken Griffin Mersana Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 27,200 shares of MRSN stock, worth $60,112. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,200

Previous 25,200 7.94%

Holding current value

$60,112

Previous $50,000 2.0%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.23 - $2.25 $2.05 Million - $3.75 Million	1,667,956 Added 60.79%	4,411,555 $8.34 Million
Q2 2024 Aug 14, 2024	SELL	$2.0 - $4.45 $1.43 Million - $3.18 Million	-715,386 Reduced 20.68%	2,743,599 $5.51 Million
Q1 2024 May 15, 2024	BUY	$2.16 - $5.94 $3.31 Million - $9.1 Million	1,532,054 Added 79.51%	3,458,985 $15.5 Million
Q4 2023 Feb 14, 2024	BUY	$1.11 - $2.34 $346,550 - $730,566	312,208 Added 19.34%	1,926,931 $4.47 Million
Q3 2023 Nov 14, 2023	BUY	$1.06 - $3.91 $1.71 Million - $6.31 Million	1,614,647 Added 2124535.5%	1,614,723 $2.05 Million
Q2 2023 Aug 14, 2023	SELL	$3.08 - $9.55 $346,761 - $1.08 Million	-112,585 Reduced 99.93%	76 $0
Q1 2023 May 15, 2023	SELL	$4.0 - $7.02 $2.05 Million - $3.6 Million	-512,915 Reduced 81.99%	112,661 $463,000
Q4 2022 Feb 14, 2023	BUY	$5.65 - $7.86 $2.54 Million - $3.53 Million	448,673 Added 253.63%	625,576 $3.67 Million
Q3 2022 Nov 14, 2022	SELL	$4.63 - $8.0 $807,990 - $1.4 Million	-174,512 Reduced 49.66%	176,903 $1.2 Million
Q2 2022 Aug 15, 2022	SELL	$2.84 - $5.0 $952,178 - $1.68 Million	-335,274 Reduced 48.82%	351,415 $1.62 Million
Q1 2022 May 16, 2022	BUY	$3.74 - $6.63 $1.41 Million - $2.51 Million	378,182 Added 122.58%	686,689 $2.74 Million
Q4 2021 Feb 14, 2022	BUY	$5.48 - $9.86 $1.43 Million - $2.58 Million	261,664 Added 558.6%	308,507 $1.92 Million
Q3 2021 Nov 15, 2021	SELL	$8.56 - $14.47 $4.64 Million - $7.85 Million	-542,280 Reduced 92.05%	46,843 $442,000
Q2 2021 Aug 16, 2021	BUY	$13.28 - $18.07 $673,508 - $916,438	50,716 Added 9.42%	589,123 $8 Million
Q1 2021 May 17, 2021	SELL	$15.31 - $26.52 $21.7 Million - $37.6 Million	-1,416,610 Reduced 72.46%	538,407 $8.71 Million
Q4 2020 Feb 16, 2021	BUY	$16.84 - $27.59 $25.9 Million - $42.4 Million	1,536,822 Added 367.49%	1,955,017 $52 Million
Q3 2020 Nov 16, 2020	SELL	$16.2 - $25.7 $2.92 Million - $4.63 Million	-180,006 Reduced 30.09%	418,195 $7.79 Million
Q2 2020 Aug 14, 2020	BUY	$5.24 - $23.4 $717,958 - $3.21 Million	137,015 Added 29.71%	598,201 $14 Million
Q1 2020 May 15, 2020	BUY	$4.41 - $9.28 $1.06 Million - $2.24 Million	241,084 Added 109.53%	461,186 $2.69 Million
Q4 2019 Feb 14, 2020	BUY	$1.45 - $6.73 $184,045 - $854,225	126,928 Added 136.23%	220,102 $1.26 Million
Q3 2019 Nov 14, 2019	BUY	$1.54 - $4.2 $19,331 - $52,722	12,553 Added 15.57%	93,174 $147,000
Q2 2019 Aug 14, 2019	BUY	$3.84 - $6.4 $130,878 - $218,131	34,083 Added 73.24%	80,621 $326,000
Q1 2019 May 15, 2019	SELL	$3.51 - $7.3 $8,789 - $18,279	-2,504 Reduced 5.11%	46,538 $0
Q4 2018 Feb 14, 2019	BUY	$3.45 - $9.72 $169,194 - $476,688	49,042 New	49,042 $200,000

Others Institutions Holding MRSN

# of Institutions

121

Shares Held

116M

Call Options Held

233K

Put Options Held

457K

View Full List

About Mersana Therapeutics, Inc.

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $215M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

More about MRSN

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account